| Maple Leaf Health Care Center | |
| 198 Pearl Street, Manchester, New Hampshire 03104 | |
| (603) 669-1660 | |
| Name | Maple Leaf Health Care Center |
|---|---|
| Location | 198 Pearl Street, Manchester, New Hampshire |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 114 |
| Occupancy Rate | 75.35% |
| Medicare ID (CCN) | 305030 |
| Legal Business Name | Pearl Street Healthcare Center Llc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1053346668 |
| Organization Name | CFN MANCHESTER-CENTER LLC |
| Address | 198 Pearl St, Manchester, NH 03104 |
| Phone Number | 603-669-1660 |
News Archive
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
In a guest post on the GlobalPost's "Global Pulse" blog, Janet Fleischman, a senior associate at the CSIS Global Health Policy Center, describes the Malawian government's "plans to launch a 'test and treat' program in which all HIV-infected pregnant women will immediately be put on antiretroviral treatment drugs for life."
› Verified 8 days ago
| NPI Number | 1477273100 |
| Organization Name | BH MAPLE LEAF LLC |
| Address | 198 Pearl St, Manchester, NH 03104 |
| Phone Number | 603-669-1660 |
News Archive
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
In a guest post on the GlobalPost's "Global Pulse" blog, Janet Fleischman, a senior associate at the CSIS Global Health Policy Center, describes the Malawian government's "plans to launch a 'test and treat' program in which all HIV-infected pregnant women will immediately be put on antiretroviral treatment drugs for life."
› Verified 8 days ago
| NPI Number | 1588944896 |
| Organization Name | PEARL STREET HEALTHCARE CENTER LLC |
| Doing Business As | MAPLE LEAF HEALTH CARE CENTER |
| Address | 198 Pearl St, Manchester, NH 03104 |
| Phone Number | 603-669-1660 |
News Archive
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
In a guest post on the GlobalPost's "Global Pulse" blog, Janet Fleischman, a senior associate at the CSIS Global Health Policy Center, describes the Malawian government's "plans to launch a 'test and treat' program in which all HIV-infected pregnant women will immediately be put on antiretroviral treatment drugs for life."
› Verified 8 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
In a guest post on the GlobalPost's "Global Pulse" blog, Janet Fleischman, a senior associate at the CSIS Global Health Policy Center, describes the Malawian government's "plans to launch a 'test and treat' program in which all HIV-infected pregnant women will immediately be put on antiretroviral treatment drugs for life."
› Verified 8 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 1 |
| Total Amount of Fines in Dollars | $5000 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 1 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 25.57 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 8.03 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 61.79 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 2.8 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 2.55 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 2.75 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 3.13 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.58 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 17.3 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 88.31 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 33.98 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 16.4 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 1 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 91.85 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 78.67 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 87.91 | 82.93 |
News Archive
Politico reports that state plans appear unchanged by this week's events. Those that were moving ahead at full speed will likely continue to do so. Those who were taking a go-slow approach have no need to change strategies now.
STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions.
Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.
In a guest post on the GlobalPost's "Global Pulse" blog, Janet Fleischman, a senior associate at the CSIS Global Health Policy Center, describes the Malawian government's "plans to launch a 'test and treat' program in which all HIV-infected pregnant women will immediately be put on antiretroviral treatment drugs for life."
› Verified 8 days ago
Hanover Hill Health Care Center Location: 700 Hanover Street, Manchester, New Hampshire 03104 Phone: (603) 627-3826 | |
Maple Leaf Health Care Center Location: 198 Pearl Street, Manchester, New Hampshire 03104 Phone: (603) 669-1660 | |
Hackett Hill Healthcare Center Location: 191 Hackett Hill Road, Manchester, New Hampshire 03102 Phone: (603) 668-8161 | |
Courville At Manchester Location: 44 West Webster Street, Manchester, New Hampshire 03104 Phone: (603) 647-5900 | |
Mount Carmel Rehabilitation And Nursing Center Location: 235 Myrtle Street, Manchester, New Hampshire 03104 Phone: (603) 627-3811 | |
Saint Teresa Rehabilitation & Nursing Center Location: 519 Bridge Street, Manchester, New Hampshire 03104 Phone: (603) 668-2373 |